enzo tramontano

Jan 282016
 

BalzariniJAN BALZARINI obtained his Master Degree in Engineer in Chemistry and Agriculture, Specialisation in Industrial Microbiology and Biochemistry, at Katholieke Universiteit Leuven, Belgium.  In 1984 obtained hisPhD  in Agricultural Sciences in Prof. Erik De Clercq Lab. From October 2001 is Full Professor (“Gewoon Hoogleraar”) at the Faculty of Medicine, and from 2006  is head of the Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.Member of the Grand Jury of the René Descartes-Prize of the European Commission. Honorary Visiting Professor at Cardiff University, School of Pharmacy (2011-2013). Visiting Professor at the University “Tor Vergata” at Rome, Italy (2004-2013). Cardiff University Distinguished Visiting Fellow 2009/2010 at the Welsh School of Pharmacy . Approximately 160 first-author, and more than 940 co-author papers in international peer-reviewed journals between 1980 and 2014. (Co)authored 16 book chapters, ~ 130 proceeding articles, and more than 500 published abstracts between 1980 and 2014. Among his scientific interests there are: chemotherapy of (retro)viral diseases with special emphasis on herpes virus infections (i.e. herpes simplex, varicella-zoster virus, cytomegalovirus), influenza virus and retrovirus infections (including AIDS); chemotherapy of malignant diseases, including combined gene/chemotherapy of cancer; molecular mechanisms of action and pharmacology of antiviral and antitumor compounds, in particular nucleoside and nucleotide analogues and carbohydrate-binding agents; Molecular mechanisms of antiviral and anticancer drug resistance; virus replication (i.e. DNA polymerase, reverse transcriptase) and virus entry as target of therapeutic intervention; prodrug technologies to improve the antiviral/cancer drug activity of (non)nucleoside analogues. He received numerous awards, including :  Research (ISAR) (Laureat) “Carbohydrate-binding agents: a novel tool for the inhibition of enveloped viruses”, in 2011 Pharmacia-ASPET Award for Experimental Therapeutics-2011 of the American Society for Pharmacology and Experimental Therapeutics .       “Discovery and development of novel concepts and drug leads for antiviral and anticancer chemotherapy”. He is holder of more than twenty approved and/or submitted patent applications of important antiretroviral drugs.

 BeckerSTEPHAN BECKER is the director of the Institute of Virology at the Philipps University Marburg. He studied Pharmaceutical Sciences and performed his PhD on energy metabolism of tumor cells. Then he moved to the Institute of Virology in Marburg where he started working with filoviruses, mainly on replication strategies of these highly pathogenic viruses. In 2006 he was appointed as a group leader at the Robert Koch Institut, Berlin before accepting a full professorship at the Philipps University, Marburg in 2008. He is speaker of the German research foundation funded collaborative research center 1021 “Sonderforschungsbereich 1021” and coordinates the section “Emerging Infections” of the German Center for Infection Research. Research interests are morphogenesis and pathogenicity of viruses causing hemorrhagic fevers. Viruses crossing the species barrier between animal and man (zoonotic viruses) represent a growing problem for our societies since the interfaces between animals and humans became more extended due to intensive land usage worldwide. In rare cases animal viruses can cause severe partially fatal diseases in the human host. Understanding the pathogenesis of those infections might provide new strategies to treat those diseases. A classic example for a viral zoonosis is Marburg virus, which jumps from bats to humans causing a hemorrhagic fever with high mortality. Basic mechanisms of how Marburg virus replicates in the host cell are still not understood and are in the focus of Stephan Becker`s research activities.

BenBerkhout-3519BEN BERKHOUT studied molecular biology at the Leiden University in the Netherlands and obtained his PhD in 1986 on a research project concerning the regulation of gene expression in RNA bacteriophages, in particular translational control by means of RNA structure. He performed postdoctoral research at the Dana Farber Cancer Institute of the Harvard Medical School in the field of molecular immunology and initiated HIV-1 research at the NIH in Bethesda. BB initiated a molecular virology research line in 1991 upon his return to the Netherlands and has been at the University of Amsterdam since then. He became Head of the Laboratory of Experimental Virology and was appointed Professor of Human Retrovirology. BB is editor for several journals (Retrovirology, Virus Research, RNA Biology, Journal of Biomedical Science) and associate editor for many more (NAR, JVI, JGV, JBC etc.). BB published over 410 peer-reviewed manuscripts on diverse topics concerning HIV-1 replication, virus evolution, virus discovery, new antiviral therapeutic strategies and HIV-1 vaccine design. He received the Retrovirology Prize 2008 for his pioneering research on the structure and function of the HIV-1 RNA genome. His work received >13,400 citations and he has an H-index of 61.

BottaMAURIZIO BOTTA graduated with honors in chemistry from the University of Rome in 1974. After his military service he returned to work at the Institute of Organic Chemistry, University of Rome with the title of Fellow , under the guidance of Prof. R. Nicoletti . In 1977 he started at the University of New Brunswick (Canada) , a period of research under the guidance of Prof. K. Wiesner , earning his PhD in November 1979 . Since December 1979 resumed scientific and educational cooperation with Prof. R. Nicoletti at the University of Rome becoming a researcher . Winner of a bag NATO in 1985, he traveled for a year in laboratories of Prof. S. Hanessian of the ‘ University of Montreal (Canada) , as invited researcher .In October 1987 as an Associate Professor of Pharmaceutical Chemistry , he has held the chair of Analysis Pharmaceutical Chemistry III of the Degree Course in Pharmaceutical Chemistry and Technology of Faculty of Pharmacy, University of Siena and Bioorganic Chemistry for substitution at the Faculty of Mathematical, Physical and Natural Sciences. In the periods July-September 1987 – July September 1988 and from November to January 1989 he was Invited Professor at the University of Montreal (Canada). Since 2000 he is Full Professor of Pharmaceutical Chemistry at the University of Siena and holds the task of teaching Complements of Medicinal Chemistry and Synthesis and Design of Drugs for the Master of Science in Pharmaceutical Chemistry , University of Siena. In years 2002-2008 he held the position of Director of the Department of Drug Chemistry and Technology University of Siena. Prof. Botta was a member of the Board of the Division of Pharmaceutical Chemistry Society Italian Chemical from 1998 to 2004 , Director of the School ‘s annual ” Laboratory Methods Synthetic Medicinal Chemistry ” organizer of the workshop ” European Workshop on Drug  Design ” , now in its seventh edition and ‘ ” European Workshop in Drug Synthesis ” , at the University of Siena and he  is also a member of ‘ editorial board of scientific journalssuch as ” ChemMedChem ” , “Current Pharmaceutical Design” and ” Journal of Medicinal Chemistry ” . Since January 2008 he is Adjunct Professor at Temple University ‘s College of Science and Technology in Philadelphia (USA). The research group of Prof. Botta, currently consists of about 30 young people between undergraduates , graduate students,research grant and a single researcher , is active in the synthesis and structure determination of biologically active natural products , organic synthesis and testing of potential agents anti-viral and anti-cancer , anti-tuberculosis and synthesis of antifungal compounds . The techniques used to these studies can be summarized in conventional techniques for organic synthesis , synthesis techniques for small molecules in the solid phase , the use of enzymes , microwaves , and parallel synthesis, also  molecular modeling techniques , such as docking , molecular dynamics , QSAR and 3D QSAR Virtual screening , generation of virtual libraries are used for the discovery and optimization of potential drugs . Recently, next to the chemical synthesis and Computational has also added the analytical chemistry for the determination of parameters Pharmacokinetic necessary for the optimization of pharmacologically active molecules . The scientific production of Professor Botta is summed up in about 460 publications in journals International , 15 patents and more than 150 conference papers .

CamarasaMARIA JOSÉ CAMARASA  obtained her PhD In Chemistry by the Universidad Complutense of Madrid. She was Head of the Chemotherapy Department of IQM-CSIC; Vice-Director of Medicinal Chemistry Institute (IQM-CSIC); President of the Spanish Society of Medicinal Chemistry (SEQT) (2004-2007); member of the executive board of the Chemistry Area of ANEP (2005-2008), coordinator of Medicinal Chemistry. She is actually Research Professor (Full professor) at the Medicinal Chemistry Institute of CSIC (IQM-CSIC), Madrid, Spain; co-coordinator of the Chemical Science and Technologies area of the CSIC; Head the of nucleosides and analogues group and Member of the executive board of International Society for Nucleosides, Nucleotides and Nucleic Acids (IS3Na). She was awarded in 2001 with the prestigious René Descartes-Prize of the European Commission. Her research interests are the Medicinal Chemistry, drug-design and discovery, antivirals, anticancer, antiinfectives, pro-drugs, organic chemistry, carbohydrates, nucleosi(ti)des, peptides.

176661cROBERTO  DI SANTO Graduated in Chemistry in 1986 – “La Sapienza” University of Rome and from 1988 had a scholarship in the Pasteur Institute –Fondazione Cenci Bolognetti, Università degli Studi di Roma “La Sapienza”. In 1994 graduated in Pharmacy cum laude at “La Sapienza” University of Rome. From 1996 was Researcher SSD C07x-in Pharmaceutical Chemistry and from 1998 became associate professor. He as multiple research topics, among which chemioterapeutic drugs and antiviral drugs (HIV, HCV, Chicungunya, polio, influenza). He works also on neuroactive compounds (anti-Alzehimer).

Freed

ERIC FREED received his Ph.D. in 1990 in the laboratories of Drs. Rex Risser and Howard Temin at the University of Wisconsin-Madison and did postdoctoral work with Dr. Temin at UW-Madison in 1991.  His work in Madison focused on the function of the murine leukemia virus and HIV envelope glycoproteins in membrane fusion and virus entry.  He joined the Laboratory of Molecular Microbiology at the National Institute of Allergy and Infectious Diseases (LMM/NIAID) in 1992, where he worked with Dr. Malcolm Martin on a variety of topics relating to virus assembly and entry/post-entry events in the HIV replication cycle.  In 1997, he was appointed as a Tenure-Track Investigator in LMM/NIAID, and he was promoted to a tenured Senior Investigator position in 2002.  Dr. Freed joined the HIV Drug Resistance Program in 2003.  He was an organizer of the 2004 Cold Spring Harbor Retroviruses conference, 2006 ASCB Cell Biology of Retroviruses conference, and 2012 Keystone Conference “Frontiers in HIV Pathogenesis, Therapy and Eradication.”  In 2009, he was appointed as the first Editor-in-Chief of Viruses; he also currently serves on the Editorial Boards of Journal of Virology, Virology, Open Virology Journal, Retrovirology, Advances in Virology, Frontiers in Virology, and Journal of Molecular Biology.  Dr. Freed was selected as an NCI Mentor of Merit in 2010 for excellence in mentoring and guiding the careers of trainees in cancer research, and he was appointed to the NCI Senior Biomedical Research Service in 2011.  He is currently serving as the Chair of the NIH Virology Interest Group, a member of the NIH AIDS Discovery and Development of Therapeutics study section, and an organizer for the 2014 Keystone Conference “Viral Entry, Assembly, Exit and Spread.”  He also currently serves as an adjunct Professor in the Department of Cell Biology and Molecular Genetics at the University of Maryland, College Park and is Co-director of the University of Maryland Virology Program.

GagoFEDERICO GAGO studied Pharmacy at Complutense University, Madrid, and followed post-doctoral studies at the Physical Chemistry Laboratory,  Oxford University, under the supervision of Prof. W. Graham Richards. He  teaches Pharmacology at the Schools of Pharmacy and Medicine in the University of Alcalá (Madrid), one of the oldest European universities, where he is a Full Professor in the Department of Biomedical Sciences. He was Associate Director of the NFCR Center for Computational Drug Design (Oxford) from 2001 to 2006 and a member of the Editorial Advisory Board of Journal of Medicinal Chemistry from 2006 to 2010. Since 2001 he has been serving as an Editor-in-Chief for Journal of Computer-Aided Molecular Design and as a member of the Editorial Advisory Board for Anti-Cancer Agents in Medicinal Chemistry (formerly Current Medicinal Chemistry – Anti-Cancer Agents). Prof. Gago has authored more than 150 research papers in specialized scientific journals and has published several reviews and book chapters. His research interests are in the areas of structure-based drug design, receptor-based structure-activity relationships, and computer simulations of drug-targeted biomolecular systems including DNA, enzymes and pharmacological receptors.

HarrisREUBEN HARRIS is a Professor in the Biochemistry, Molecular Biology and Biophysics department, an Associate Director of the Institute of Molecular Virology, and a Member of the Masonic Cancer Center. He received his B.S. (1993) and Ph.D. (1997) degrees from the University of Alberta in Edmonton, Canada. He performed postdoctoral work at the Baylor College of Medicine (1997-8), at Yale University (1998), and at the Medical Research Council Laboratory of Molecular Biology (1998-2003). He joined the University of Minnesota as an Assistant Professor in the summer of 2003, became a tenured Associate Professor in 2008, and was promoted to Full Professor in 2013. As a Postdoctoral Fellow in Cambridge working with Dr. Michael Neuberger, Dr. Harris discovered a family of cellular enzymes that catalyze the conversion of the DNA base cytosine into the RNA base uracil. One member of this family is essential for generating antibody diversity (adaptive immunity) and several combine to provide protection from a wide variety of parasitic elements such as HIV (innate immunity). At least one member also becomes dyregulated in multiple human cancers and provides a major source of mutations. Dr. Harris has done pioneering studies in all of these important areas, thus far publishing over 100 manuscripts, filing 10 patents, and co-founding a company. He continues to run an academic research laboratory with multiple projects focused on the roles of these enzymes in immunity and carcinogenesis.

Mamuka KvaratskheliaMAMUKA KVARATSKHELIA is a Professor of Pharmaceutical Sciences at the Ohio State University. He received his Ph.D. and postdoctoral training studying structural and functional properties of DNA modifying enzymes in Republic of Georgia and United Kingdome, respectively. Dr. Kvaratskhelia continued his research career in Dr. Le Grice’s laboratory, where he developed the mass spectrometry-based protein footprinting approach to map nucleic acid and inhibitor binding sites on HIV-1 proteins. Since 2003 Dr. Kvaratskhelia has been a faculty member at the Ohio State University College of Pharmacy. He is a recipient of the NIH Research Career Development Award (2007-2012) and currently serves as a member of the AIDS Discovery and Development of Therapeutics study section. The primary focus of Dr. Kvaratskhelia’s research group has been to better understand HIV-1 integrase structure and function as a therapeutic target and develop novel allosteric inhibitors with potent antiviral activities. His group identified a new class of small molecules that promote aberrant, higher order multimerization of HIV-1 integrase and potently inhibit HIV-1 replication. In addition, his group has elucidated structural and mechanistic foundations of how LEDGF/p75, a key cofactor of HIV-1 integrase, directs HIV-1 preintegration complexes to actively transcribed genes. More recently, Dr. Kvaratskhelia’s group has discovered BET proteins as cofactors of murine leukemic virus (MLV) integrase and demonstrated their significance for effective MLV integration at transcription start sites. These studies have opened up a new path for improving the safety of MLV based vectors for human gene therapy.

Le griceSTUART LE GRICE received his Ph.D. from the Department of Biochemistry, University of Manchester, UK, in 1976, where he studied the mechanisms of R-factor-mediated multidrug resistance in Escherichia coli. After postdoctoral training in the United Kingdom, Germany, and the United States, he was appointed Senior Scientist in the Central Research Units of Hoffmann La Roche, Basel, Switzerland, where he worked from 1984 to 1990 evaluating HIV-1 and HIV-2 enzymes as therapeutic targets. In 1990, he joined the faculty in the Division of Infectious Diseases, Department of Medicine, Case Western Reserve University (CWRU), Cleveland, OH. Initially recruited as an Associate Professor of Medicine, he was awarded tenure in 1992, and in 1995 was promoted to Professor of Medicine, Biochemistry, and Oncology. From 1994 to 1999, he served as Director of the NIH-funded CWRU Center for AIDS Research. Dr. Le Grice joined the National Cancer Institute in 1999 as Chief of the Resistance Mechanisms Laboratory in the HIV Drug Resistance Program, Center for Cancer Research (CCR), and in 2005 was appointed to the Senior Biomedical Research Service. In 2006, he was appointed Head of the Center of Excellence in HIV/AIDS & Cancer Virology, CCR. He is a member of the CCR HIV and Cancer Virology faculty, Chemistry and Biology faculty, and the Steering Committee of the Molecular Targets Discovery Program. In addition to serving on the Editorial Board of the Journal of Biological Chemistry, Dr. Le Grice has been an ad hoc (1990-1999) and permanent Study Section member of NIH AIDS review panels (2000-2004), as well as an ad hoc reviewer for several international funding agencies.

21aec95FRANCO LORI  founded ViroStatics in 2005, serving as President and Chief Executive Officer. With 20 years of extensive experience in Biotech management, Dr. Lori has overseen the successful start-up of three biotechnology companies. Dr. Lori also has experience in investigative preclinical and clinical research interacting with a network of clinical, pharmaceutical, government, and basic science researchers in the USA, Europe, South America, and Africa. 
In 2000, Dr. Lori was recognized as a global “Hero in Medicine” for his achievements in HIV therapy. He has co-authored over 100 international peer-reviewed publications. Dr. Lori received his MD from the University of Parma and earned his PhD degree at the University of Pavia, Italy. He was Senior Investigator in the Laboratory of Tumor Cell Biology at the National Cancer Institute before co-founding RIGHT in 1994 where he serves as Board Director.
Fields of interest: drug development, nanotechnology, precision medicine, incurable diseases

Matyus

PETER MATYUS achieved his M.S. in Synthetic Organic Chemistry at in 1975; the M. Litt. (Doctor title) in 1980; and the Degree in Medicinal Chemistry at the Technical University Budapest 1981. He obtained his habilitation at the A. Szent-Györgyi Univ., Szeged on 1997; and the C.Sc., D.Sc. at the Hungarian Academy of Sciences. He pursuived with several Postdoctoral Fellowships of the A.v. Humboldt-Foundation (Inst. für Organische Chemie und Biochemie), University of Bonn (H. Wamhoff) (1982-1984, 1989, 1990); of the Ciba-Geigy Foundation for Promotion of Sciences Japan (Inst. for Chem. Res.), University of Kyoto (K. Tanaka) 1992-93; and the fellowship of the Australian Natl. University (John Curtin School of Medical Research) (G. Barlin) Canberra 1993 (1 month), and on 1994 (3 months). From 1997 he is the Head of the Department of Organic Chemistry at the Semmelweis University. Since 2008 he is the Director of the Drug Discovery and Safety Centre at the Semmelweis University. His memberships: 1999-2007 Chair of the Division of Organic and Medicinal Chemistry of the Hungarian Chemical Society (re-elected twice); 2007-2011 President of the Hungarian Chemical Society; 2002-2006 Member of the Council of Scientists, INTAS (EU, Brussels; re-elected); International Advisory Board of ChemMedChem. Associate Editor of Future Med. Chem; 2004-2010 Member of the Executive Committee, and Chair of Education and Training Committee of European Federation for Medicinal Chemistry (re-elected); Member of Medicinal Chemistry Subcommittee of IUPAC; Member of ACS; Founder and Board member of Paul Ehrlich MedChem Euro-PhD Network. He also won several awards such as: Zemplén-Prize, Hungarian Academy of Sciences 1989; ‘Nívó’-Prize, Hungarian Chemical Society, 1996. Genius Prize, Committee of the Hungarian Inventors, (twice) 1996, 1998; Jedlik Ányos Prize, Hungarian Patent Office, 2002; Kazay Prize, Hungarian Pharmaceutical Society, 2004; Than Károly Prize, Hungarian Chemical Society, 2005; Náray-Szabó Gábor Prize, Hungarian Chemical Society, 2006; Bruckner Prize, Hungarian Academy of Sciences 2009; PhD-Educational Prize, Semmelweis University, 2011. His research interests are medicinal chemistry of cardiovascular and central nervous systems, molecular modelling and synthesis of biologically active compounds; synthetic and mechanistic chemistry of pyridazines and nitrogen containing heterocycles.

MertensTHOMAS MERTENS studied Chemistry in Bonn and Medicine in Cologne (1968-1976). He obtained the MD Thesis (Dr. med.) on 1976 and his Habilitation on 1984. Thomas Mertens was medical assistant, training in internal medicine and surgery (1976–1977); he continued with a research fellowship for the postdoctoral training in immunology, virology and diagnostics, Institute of Virology, University of Cologne (1977–1985). In 1983 he reached the Board Certification in Microbiology and Epidemiology of Infectious Diseases. In 1985 he became Professor (C2) at the Institute of Virology, University of Cologne, from 1991 to 1998 he was Professor (C3), in the Dept. of Virology, Ulm University. He was Temporary Director of the Dept. Medical Hygiene, Ulm University Hospital from 1991 to 1992; and Dean of Studies at the Medical Faculty, Ulm University from 2003 to 2006. Since 1998 he is the Director of the Institute of Virology at the Ulm University Hospital. His research focuses: mechanisms of resistance of antiviral substances towards herpes viruses; the analysis of the biological function of the viral gene UL97; new targets for antiviral interference against human cytomegalovirus (HCMV); molecular mechanisms and functional relevance of host-cell genes modulation by HCMV; viral tegument proteins and Morphogenesis of HCMV; new organ culture model for analysis of HCMV infection; the characterization and function of G-protein coupled receptor homologs of HCMV; and the Clinical Virology.

PalùGIORGIO PALÙ received his M.D. degree from the University of Padova (1973) and the Specialty diplomas in Oncology (1976) and General Pathology (1978) from the University of Pavia. He worked as a Postdoctoral Fellow and Research Associate at the Tumor Institute, Jules Bordet, Université Libre, Bruxelles (1975), the Chester Beatty Research Institute-Royal Marsden Hospital, Royal Cancer Institute, London University, UK (1976-79), the Department of Pharmacology, Yale University, New Haven, CT (1980).Assistant Professor in Microbiology, University of Parma (1980-82); Associate Professor in Virology, University of Padova (1983-1989); Visiting Professor, Department of Molecular Biochemistry and Biophysics, Yale University, 1982,1984,1986; Division of Virology, National Institute for Medical Research, Mill Hill, London, UK, 1980,1985,1987; Division of Human Retrovirology, Dana Farber Cancer Institute, Harvard Medical School (1990), Full Professor of Microbiology and Virology (since 1989), University of Padova. Director at the University of Padova: Institute of Microbiology (1991-1999); Department of Histology, Microbiology and Medical Biotechnologies, (1999-2002); Department of Molecular Medicine (since 2012); Head of the Padova GMP Cell-factory and of the Unit of Clinical Microbiology and Virology, Padova University Hospital (since 1996). Coordinator, PhD Course/School in Virology (since 1998) and in Biomedicine (since 2007); Member of the Board of the International PhD Programmes in Molecular Medicine, University of Ulm, Germany (since 2008), in Biomedicine and Translational Neurosciences, Temple University, Philadelphia, USA (since 2011); Adjunct Professor at the Medical School and at the Faculty of Sciences, University of Temple; Pro-Rector, University of Padova (2002-2004); Dean, Faculty of Medicine, University of Padova (2004-2011). GP has also served as a member of the scientific-technical Committee of the Italian Drug Agency (AIFA), of the directory Board of the Italian AIDS Commission, of the Istituto Superiore di Sanità (Rome) and of the Institute of Human Virology (Baltimore). Professor Palù is the running President of the European Society for Virology. Giorgio Palù has long-standing experience in the study of pathogenesis of viral infections and the design of viral and non-viral vectors for gene transfer, somatic gene therapy and vaccinology. He has made relevant contributions to the study of antimicrobial therapy and resistance and anticancer therapy with more than 400 publications and 10 patents. His basic research has provided a platform for finding new targets for antiviral therapy and new antivirals based on peptides and small molecules able to disrupt the interface of protein-protein interactions essential for viral replication.

CARLO FEDERICO PERNOCARLO FEDERICO PERNO is Professor of Virology at the University ‘of Rome Tor Vergata and Primary Unit’ Complex Molecular Virology, Policlinico Tor Vergata. Pin is also director of the School of Specialization in Microbiology and Virology. He graduated in 1980 in Medicine, Universita ‘di Roma “La Sapienza” with honors, in 1983 specializes in Oncology.
From 1986 to 1989 he was Assistant Professor at the National Cancer Institute. He works in the field of ‘AIDS since 1985, and has contributed to the discovery of some of the drugs still used for the treatment of HIV infection. He is a fellow of numerous research funds obtained from various public and private institutions, including EEC, CNR, Ministry of Health ‘, Ministry of University’ and Research, UNESCO, aimed at scientific and clinical research mainly on viral infections. Author of more ‘than a thousand scientific articles and presentations at international conferences. He received the 2001 Descartes Prize of the Community ‘European Excellence Research.

summaVINCENZO SUMMA  Head of Chemistry  IRBM Science Park spa from February 2010. IRBM Science Park is a research centre formally a spin-off of the Merck Research Laboratories locate in Rome. He graduated in  Chemistry at Università degli Studi di Roma ‘La Sapienza’ in 1991 and in 1996 obtained his Ph.D in Organich Chemistry at Bergische Universität Wuppertal. From 1992 to 1994  was researcher at University of Rome “La Sapienza” . He became Research Fellow Merck  from  March 1996 to  August 2001 . Here was promoted Senior Research Fellow (September 2001 );Senior Investigator Merck  (November 2005 ) and Director in the medicinal chemistry department  from November 2007to October 2009. From June 2010 is  Associate Researcher CNR-ITB National Research Council – Institute for Biomedical Technologies and from April 2013  Member of the Board of Directors at CNCCS Consortium (IRBM SP – Consiglio Nazionale delle Ricerche – Istituto Superiore di Sanità)

woehrl_foto

BIRGITTA M. WÖHRL  studied biology in Regensburg, Germany and in Cardiff, UK. She obtained her doctoral degree in bacterial genetics from the University of Osnabrück, Germany, in 1989. During her postdoctoral training at the Max-Planck-Institute for Genetics in Berlin and at Case Western Reserve University, Cleveland, Ohio, she worked on biochemical aspects of retroviral reverse transcriptases. In 1992 she was awarded a five year “AIDS-stipend” from the German Ministry of Education and Research. She joined the Max-Planck-Institute for Molecular Physiology in Dortmund, Germany in 1994 working on retroviral replication, AZT resistance and genetically engineered thymidylate kinases. In 2002 she received a position at the University of Bayreuth, Germany in the Department of Biopolymers and was promoted to Professor in 2005. Her research interests include the structure and function of retroviral enzymes, and of viral and cellular factors involved in HIV transcription, the elucidation of resistance mechanisms against antiviral drugs, the mechanism of action of antiviral compounds, and the replication of foamy viruses.

Jan 282016
 

001Fatima Ezzahra AGHARBAOUI                     Università degli Studi di Messina, Italy

Antonella ARRIDU                                            University of Cagliari, Italy

Jessica BOGS                                                      Federal Research Institute for Animal Health, Germany

Marta CADEDDU                                               University of Cagliari, Italy

Roberta CADONI                                               University of Sassari, Italy

Arianna CALISTRI                                            University of Padua , Italy

Valeria CANNAS                                                University of Cagliari,Italy

Ilaria CARLI                                                        University of Padua, Italy

Michele CELESTINO                                       University of Padua, Italy

Laura CONTARDI                                             University of Parma, Italy

Angela CORONA                                                University of Cagliari, Italy

Gianluca DAINO                                                University of Cagliari, Italy

Laura DE LUCA                                                 University of Messina, Italy

Claudia DEL VECCHIO                                    University of Padua, Italy

Ruth DEME                                                         Semmelweis University, Budapest

Simona DISTINTO                                            University of Cagliari

Francesca ESPOSITO                                        University of Cagliari, Italy

Nicole GRANDI                                                  University of Cagliari, Italy

Pouya HASSANDARVISH                                Faculty of Medicine, Kuala Lumpur,Malaysia

Samira KHIAR                                                     Institut Pasteur de Paris, France

Florencia NataliaLINERO                                 Inflammation Research Center (IRC), Belgium

Valentina Noemi MADIA                                  Università la Sapienza Roma,Italy

Riccardo MARTINI                                            University of Siena, Italy

Serena MASSARI                                                University of Perugia, Italy

Elena MATYUGINA                                           Engelhardt Institute of Molecular Biology RAS Moscow, Russia

Rita MELEDDU                                                  University of Cagliari, Italy

Antonella MESSORE                                         Università la Sapienza Roma,Italy

Monica MEOLA                                                 Istituto Superiore di Sanità, Italy

Marta MURREDDU                                           Georgetown UniversityWashington,USA

Vasanthanathan POONGAVANAM                University of Southern Denmark

St Patrick REID                                                   USAMRIID Frederick, MD,USA

Udaya Pratap SINGH          Institute of Agriculture, Technology & Sciences, India

Axel SCHUBERT                                                Ulm University Medical Center,Germany

Lora SIMEONOVA                                             Bulgarian Academy of Sciences,Sofia, Bulgaria

PavelSOLYEV                                                      Russian Academy of Sciences,Moscow,Russia

ŁukaszŚWIĄTEK                                                Medical University of Lublin,Poland

Oriana TABARRINI                                            University of Perugia, Italy

Maria ElenaTERLIZZI                                       Università degli Studi di Torino, Italy

Graziella TOCCO                                                 University of Cagliari , Italy

Marta TOFFOLETTO                                         University of Padua, Italy

Janne TYNELL                                                   National Institute for Health and Welfare Helsinki,Finland

Finny VARGHESE                                             University of Helsinki, Finland

 

Sep 302013
 

Over the recent years, drug discovery via high throughput screening (HTS) has moved beyond the boundaries of pharmaceutical companies and been successfully integrated into research programs of many academic institutes. These efforts have taken advantage of the availability of diverse libraries of small molecules, either as pure entities or natural product extracts. However, identification of candidate drugs benefits from an in-depth understanding of potential pitfalls of HTS, which can include (i), storage of compound libraries (ii), stability and cost of assay reagents (iii), robustness of the assay and (iv), access to bioinformatics to analyze the wealth of data that results from performing multiple assays on 250,000 – 500,000 compounds. Beyond these challenges, successful HTS is an iterative process requiring close co-operation with programs of structural biology, medicinal chemistry and clinical research.

With these issues in mind, the Innovative Approaches for Identification of Antiviral Agents Summer School (IAAASS) aims to provide an informal and interactive environment to review the application of HTS techniques to identification of novel and clinically-significant antiviral drugs. The Summer School is targeted to researchers at an early stage in their career, combining examples of drug discovery from internationally-recognized experts in the field with informal, small-group thematic discussion sessions. Evening sessions will allow students to present their work in the form of either a poster or oral presentations and receive feedback from their colleagues. The Organizing Committee welcomes you to the Hotel Flamingo, Santa Margherita di Pula, located on the south tip of Sardinia, and looks forward to sharing with you their experience on current and future strategies for identifying novel antiviral agents targeted to clinically-significant diseases.

Acknowledgements:

The Organizing Committee would like to thank the following:
Regione Autonoma Sardegna, for their generous financial support for the meeting;

Università di Cagliari, for logistical support;

Gemma Marcias and Luca Zinzula for website preparation.

The meeting is being held in partnership with:
European Society for Virology (ESV)
Società Italiana di Virologia (SIV)
Società Italiana di Microbiologia Generale e Biotecnologie Microbiche (SIMGBM)
Università di Cagliari, PhD program in “Human and Environmental Biology and Biochemistry”

IAAASS 2012 Participants

 IAAASS 2012 Participants  Comments Off on IAAASS 2012 Participants
Sep 262013
 
Sep 262013
 

Stefano Alcaro (*1966) obtained his doctoral degree in Pharmacology, Pharmacognosy and Toxicology at the Università La Sapienza di Roma. After his PhD he continued with a postdoctoral fellowship in the laboratory of Computional Chemistry of the Department of Chemistry at the Columbia University, New York (Prof. W. Clark Still team). On 1996 he has got his first permanent position as Medicinal Chemistry researcher at the Faculty of Pharmacy at the Università Magna Græcia of Catanzaro. From 2002 to 2011 he was Associate Professor in the same scientific sector (CHIM/08) at the University of Catanzaro. From 2011 he is Full Professor in the same academic institution. His main teaching course at the Università Magna Græcia of Catanzaro is Medicinal Chemistry and Toxicology I.
Stefano Alcaro is co-author of about 100 original publications on peer reviewed international journals, 4 books chapters, 2 international diffused volumes and over 100 national and international communications. His research interests are related to drug design and hit identification of bioactive compounds by means of computational methods especially in the fields of anticancer and antiviral therapies.

Daniel Appella was graduated from the University of Wisconsin-Madison, 1998, with Ph.D. in Organic Chemistry. He continued with a postdoc at MIT, also working in the area of organic chemistry. He was an assistant professor at Northwestern University, in the Chemistry Department, from 2001 to 2004. In 2005 he moved to NIH as a tenure track PI, promoted to tenure at NIH in 2008. Currently, he is Chief of the Synthetic Bioactive Molecules Section, one of the labs in the Laboratory of Bioorganic Chemistry that is part of the National Institute of Diabetes and Digestion and Kidney Diseases (NIDDK). Appella’s laboratory research uses synthetic organic chemistry to create new molecules with unique biological activity with the potential to evolve into a new strategy for diagnosing or treating a disease. Within their research, most of the time goes for the molecules synthesis, and the use of a large amount of molecular modeling and biophysical techniques to study the molecules they make. Different projects of the Appella’s group are: A) exploration of the incorporation of carbocyclic rings and sidechains into the backbone of several different peptide nucleic acids (PNAs) in order to provide the basis for design of PNA-based sensors and to develop new diagnostic techniques based on our modified PNAs; B) examination of sidechain-bearing polyamines as molecular scaffolds for the display of RNA binding groups, in order to develop syntheses of these polyamines, making combinatorial libraries of these molecules, and studying their binding properties to two important RNA targets (TAR RNA and RRE RNA of HIV); C) inspired by a recent identification of a few novel molecules that reactivate mutant p53 to bind its DNA target, the 3rd research topic is to design a new class of molecules that reactivate mutant p53 in order to probe the unique mechanism that allows small organic molecules to restore normal activity to a mutant protein.

Jonas Blomberg (*1944) is a professor emeritus of Clinical Virology at Uppsala University. MD 1974 at the School of Medicine at Göteborg University and PhD 1977 at Medical Biochemistry, GU. He was then a post-doc 1979-1981 at the National Cancer Institute under Dr John Stephenson, on Retroviruses. He became assistant Professor 1981 (Virology) in Lund, and professor (Clinical Virology, chair), at the Medical Faculty of Uppsala University 1996. He is a professor emeritus there since 2011. He is since 1979 a board certified clinical virology specialist, heading diagnostic virology labs at Lund and Uppsala. I was the main supervisor of 14 PhD students. He has published 190 papers in peer reviewed journals. The lines of investigation are 1. Diagnosis of microbial disease. Being a clinical virologist, this is a natural preoccupation. It is currently dominated by the development of broadly targeted multiplex techniques for detection of pathogen nucleic acid, and antibodies to pathogens. 2. Retroviruses. Human retroviruses, HTLV, HIV, XMRV and human endogenous retroviruses were studied. Much of the study is done with bioinformatics, where he collaborated with ass. prof. Göran Sperber in the creation of RetroTector, a bioinformatics tool for detecting and characterizing proviral sequences in genomic databases. The bioinformatics and the multiplex methods are useful for basic retroviral research and for diagnostic development. Currently, the disease myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is in my focus.

Maria José Camarasa obtained her PhD In Chemistry by the Universidad Complutense of Madrid. She was Head of the Chemotherapy Department of IQM-CSIC; Vice-Director of Medicinal Chemistry Institute (IQM-CSIC); President of the Spanish Society of Medicinal Chemistry (SEQT) (2004-2007); member of the executive board of the Chemistry Area of ANEP (2005-2008), coordinator of Medicinal Chemistry. She is actually Research Professor (Full professor) at the Medicinal Chemistry Institute of CSIC (IQM-CSIC), Madrid, Spain; co-coordinator of the Chemical Science and Technologies area of the CSIC; Head the of nucleosides and analogues group and Member of the executive board of International Society for Nucleosides, Nucleotides and Nucleic Acids (IS3Na). She was awarded in 2001 with the prestigious René Descartes-Prize of the European Commission.
Her research interests are the Medicinal Chemistry, drug-design and discovery, antivirals, anticancer, antiinfectives, pro-drugs, organic chemistry, carbohydrates, nucleosi(ti)des, peptides.

Mamuka Kvaratshelia Mamuka Kvaratskhelia obtained his Ph.D. degree in Biochemistry from the Russian Academy of Sciences, continued his career in the Biological Chemistry Department at the Unilever-John Innes Center (Norwich) and University of Dundee, United Kingdom and is currently working at the National Cancer Institute (NCI), Frederick, MD. He is actually Associate Professor at The Ohio State University, College of Pharmacy, Center for Retrovirus Research and Comprehensive Cancer Center, Columbus, OH. Research in the Kvaratskhelia laboratory focuses on elucidating the composition and architecture of key HIV replication complexes and exploiting the knowledge obtained for discovery of new anti-retroviral therapies. His research look with particular interest at the biochemistry of HIV integration, in order to define molecular interactions essential for HIV replication and uncover new structural targets for developing antiretroviral compounds; and the allosteric inhibitors of HIV integrase, to discover novel types of clinically useful agents that could complement current antiviral therapies. Particular interest is addressed to the proteomics approach to better understating the complex network of virus-host interactions required for HIV infection.

Thierry Langer (*1962) began his career at Leopold-Franzens-University of Innsbruck in 1992 after completing a post doctoral fellowship at the Université Louis Pasteur, Strasbourg, France with Prof. C.-G. Wermuth. Since that time, he established the Computer Aided Molecular Design Group, was appointed Associate Professor of Pharmaceutical Chemistry in 1997, and served as Head of the Institute of Pharmaceutical Chemistry and of the Pharmaceutical Chemistry Department in 1998 and 1999. His research interests range from medicinal chemistry, including theoretical pharmaceutical chemistry, drug design, and pharmacophore modeling as well as QSAR and 3DQSAR molecular modeling techniques. His scientific work, which has culminated in more than 160 original articles, book chapters, and invited reviews, together with more than 200 lectures and poster presentations at scientific meetings, led to the founding of the spin-off company Inte:Ligand GmbH, in which he also was CEO from 2003 to 2008. With April 2008, Prof. Langer has left University of Innsbruck to been appointed CEO of Prestwick Chemical Inc., Strasbourg-Illkirch, France. Prof. Langer holds an M.S. degree in Pharmacy and a Ph.D. in Medicinal Chemistry from the University of Vienna, Austria. He is fluent in English, French, and German.

Stephan Ludwig obtained in 1993 his PhD at the Institute of Virology of University of Giessen. After the Habilitation (2000) in Molecular Biology at the Julius-Maximilians-Universität Würzburg, he was research assistant at the Institute of Virology, University of Giessen (1993-1994). In 1995 he became group leader at the Institute for Medical Radiation and Cell Research (MSZ), University of Wuerzburg, from 2001 to 2002 he earned a senior research fellowship at the MSZ. Stephan Ludwig was University Professor at the Institute of Molecular Medicine (IMM), University of Duesseldorf (2002-2004). Since 2004 he is University Professor and Director at the Institute for Molecular Virology (IMV) at the Center for Molecular Biology of Inflammation (ZMBE), University of Muenster. He was Managing Director of ZMBE (2006-2008) and he is actually Vice-Rector for Research at the Westfälische Wilhelms-Universität. Within his affiliation we count: since 2007 the Scientific coordination of the service platform “Integrated Functional Genomics” (IFG), University of Muenster; since 2008 the coordination of the nationwide research network “FluResearchNet” (initiated and supported by the German Ministry for Education an Research – BMBF) and since 2009 the coordination of the “National Platform for Zoonoses Research” (initiated and supported by the BMBF).
Research at the Institute of Molecular Virology (headed by Prof. Dr. Stephan Ludwig) focusses on intracellular signal transduction pathways and their impact on viral infection and inflammation with a major interest for: influenza viruses, via gathering knowledge about the cellular processes which control virus replication; signalling pathways involved in inflammatory responses, with the molecular analysis of pro-inflammatory cytokine expression and signalling mechanisms during the acute-phase response and the analysis of signalling pathways during inflammatory activation of the endothelium.

Peter Matyus achieved his M.S. in Synthetic Organic Chemistry at in 1975; the M. Litt. (Doctor title) in 1980; and the Degree in Medicinal Chemistry at the Technical University Budapest 1981. He obtained his habilitation at the A. Szent-Györgyi Univ., Szeged on 1997; and the C.Sc., D.Sc. at the Hungarian Academy of Sciences. He pursuived with several Postdoctoral Fellowships of the A.v. Humboldt-Foundation (Inst. für Organische Chemie und Biochemie), University of Bonn (H. Wamhoff) (1982-1984, 1989, 1990); of the Ciba-Geigy Foundation for Promotion of Sciences Japan (Inst. for Chem. Res.), University of Kyoto (K. Tanaka) 1992-93; and the fellowship of the Australian Natl. University (John Curtin School of Medical Research) (G. Barlin) Canberra 1993 (1 month), and on 1994 (3 months). From 1997 he is the Head of the Department of Organic Chemistry at the Semmelweis University. Since 2008 he is the Director of the Drug Discovery and Safety Centre at the Semmelweis University. His memberships: 1999-2007 Chair of the Division of Organic and Medicinal Chemistry of the Hungarian Chemical Society (re-elected twice); 2007-2011 President of the Hungarian Chemical Society; 2002-2006 Member of the Council of Scientists, INTAS (EU, Brussels; re-elected); International Advisory Board of ChemMedChem. Associate Editor of Future Med. Chem; 2004-2010 Member of the Executive Committee, and Chair of Education and Training Committee of European Federation for Medicinal Chemistry (re-elected); Member of Medicinal Chemistry Subcommittee of IUPAC; Member of ACS; Founder and Board member of Paul Ehrlich MedChem Euro-PhD Network. He also won several awards such as: Zemplén-Prize, Hungarian Academy of Sciences 1989; ‘Nívó’-Prize, Hungarian Chemical Society, 1996. Genius Prize, Committee of the Hungarian Inventors, (twice) 1996, 1998; Jedlik Ányos Prize, Hungarian Patent Office, 2002; Kazay Prize, Hungarian Pharmaceutical Society, 2004; Than Károly Prize, Hungarian Chemical Society, 2005; Náray-Szabó Gábor Prize, Hungarian Chemical Society, 2006; Bruckner Prize, Hungarian Academy of Sciences 2009; PhD-Educational Prize, Semmelweis University, 2011. His research interests are medicinal chemistry of cardiovascular and central nervous systems, molecular modelling and synthesis of biologically active compounds; synthetic and mechanistic chemistry of pyridazines and nitrogen containing heterocycles.

Thomas Mertens studied Chemistry in Bonn and Medicine in Cologne (1968-1976). He obtained the MD Thesis (Dr. med.) on 1976 and his Habilitation on 1984. Thomas Mertens was medical assistant, training in internal medicine and surgery (1976–1977); he continued with a research fellowship for the postdoctoral training in immunology, virology and diagnostics, Institute of Virology, University of Cologne (1977–1985). In 1983 he reached the Board Certification in Microbiology and Epidemiology of Infectious Diseases. In 1985 he became Professor (C2) at the Institute of Virology, University of Cologne, from 1991 to 1998 he was Professor (C3), in the Dept. of Virology, Ulm University. He was Temporary Director of the Dept. Medical Hygiene, Ulm University Hospital from 1991 to 1992; and Dean of Studies at the Medical Faculty, Ulm University from 2003 to 2006. Since 1998 he is the Director of the Institute of Virology at the Ulm University Hospital. His research focuses: mechanisms of resistance of antiviral substances towards herpes viruses; the analysis of the biological function of the viral gene UL97; new targets for antiviral interference against human cytomegalovirus (HCMV); molecular mechanisms and functional relevance of host-cell genes modulation by HCMV; viral tegument proteins and Morphogenesis of HCMV; new organ culture model for analysis of HCMV infection; the characterization and function of G-protein coupled receptor homologs of HCMV; and the Clinical Virology.

Ali Mirazimi received his Ph.D In infection Biology in 2000 from the Department of Microbiology, Tumour biology and Cell biology at Karolinska Institute. Short after, he received a junior lecturer position at Karolinska Institute. At 2002 he received a position as Molecular virologist at Swedish Institute for Infectious Disease control. At 2006 he achieved Associate professor position at Karolinska Institute. He has been the head of the BSL-4 Virology Unit at Centre for Microbiological Preparedness at Swedish Institute for Infectious disease control. Today, he is Coordinator for a large collaborative research program with focus on Crimean Congo hemorrhagic fever virus, which founded by European commission. He has also a position as strategically advisor for Swedish national Veterinary Institute. His group is interested to understand the molecular pathogenesis of emerging viruses. The major focus is the role of Innate Immunity for controlling the viral replication cycle. He is also interested to investigate the virus-host cell interaction and virus biology.

 Giorgio Palù received the Specialty diplomas in Oncology (1976) and General Pathology (1978), was appointed Postdoctoral Fellow and Research Associate at the Tumor Institute, Jules Bordet, Université Libre, Bruxelles (1975), the Chester Beatty Research Institute-Royal Marsden Hospital, Royal Cancer Institute, London University, UK (1976-79), the Depart. of Pharmacology, Yale University, New Haven, CT (1979-80), Assistant Professor in Microbiology, University of Parma (1980-82), Associate Professor in Virology, University of Padova, Medical School (1983-1989), Visiting Professor, Depart. of Molecular Biochemistry and Biophysics, Yale University, 1982,1984,1986; Division of Virology, National Institute for Medical Research, Mill Hill, London, UK, 1980,1985,1987; Division of Human Retrovirology, Dana Farber Cancer Institute, Harvard Medical School, Full Professor of Microbiology and Virology (since 1989), University of Padova Medical School. Director of the Institute of Microbiology, University of Padova, Medical School (1991-1999), of the Depart. of Histology, Microbiology and Medical Biotechnologies, University of Padova, Medical School (1999-2002); Head of the Unit of Clinical Microbiology and Virology, Padova University Hospital/Veneto Region (since 1996); Member of the Executive Committee of the Interdipartimental Centre for Innovative Biotechnologies, Padova University (since 1992); the Interuniversity Consortium of Nanotechnologies (since 2003); the Galilei Scientific Park (since 2001); the Padua start-up company incubator (since 2003); the Tissue-Tech Consortium (since 2004); the Biotechnological Association for Oncology Research (ABO, since 2003). Coordinator, PhD Course/School in Virology (since 1998) and in Biomedicine (since 2007); Member of the Board of the International PhD Programmes in Molecular Medicine, University of Ulm, Germany (since 2008), in Biomedicine and Translational Neurosciences, Temple University, Philadelphia, USA (since 2011); Pro-Rector, University of Padova (Foreign affairs and international research, 2002-2004); Dean, Faculty of Medicine and Surgery, University of Padova (2004-2011), Director of the Padova GMP Project (Cell-factory of the Veneto Region – Italy); Director of the Department of Molecular Medicine, University of Padova (since 2012). He is also Head of the Center of Biomedicine, Clinical Microbiology and Virology and GMP facility of the Padua University Hospital. He has a long-standing experience in the study of pathogenesis of viral infections and the design of viral and non-viral vectors for gene transfer, somatic gene therapy and vaccinology and for regenerative medicine. He has made relevant contributions in the study of antimicrobial therapy and resistance and anticancer therapy with more than 350 publications and 10 patents. His basic research has provided a platform for finding new targets for antiviral therapy and new antivirals based on peptides and small molecules able to disrupt the interface of protein-protein interactions essential for viral replication.

Sep 262013
 

Approaches for Identification of Antiviral
Agents Summer School (IAAASS)

September 30 – October 4, 2012
Santa Margherita di Pula, Sardinia

Provisional Program

Sunday, September 30th – Registration Day

13:00 pm Buffet lunch

Afternoon – Free

7.00 pm Welcoming Remarks

7.15 pm Development of new antiviral agents: from peptides to small molecules, Giorgio Palù, University of Padova, Italy

8.00 pm Informal Dinner

Monday, October 1st

Breakfast

Morning session

Plenary lectures

9.00 – 9.45 am A dynamic interplay between HIV-1 integrase subunits as a new therapeutic target, Mamuka Kvaratskhelia, The Ohio State University, Columbus, USA.

9.55 – 10.40 am Influenza viruses and host cell signaling – towards identification of novel targets for antiviral therapy, Stephan Ludwig, University of Muenster, Germany.

10.50 – 11.10 am Coffee break

11:15 – 12.00 pm  Multi-targeting with one single drug, Peter Matyus, Semmelweis University, Hungary

12.10 – 12:55 pm Therapy of Human Cytomegalovirus – actual situation, problems and future perspectives, Thomas Mertens, Universitätsklinikum Ulm, Germany

1:00 pm Lunch

Afternoon session

3.30 – 5:00 pm Thematic Group Discussions

5:00 – 6.00 pm Coffee break/ Poster Session 1

Short Talks

6.00 – 6.15 pm From a Protein Crystal to an Effective Hepatitis C Vaccine: The Hard Way of Structural Biology, Valeria Fadda, University of St Andrews, St Andrews (UK)

6.15 – 6.30 pm Structural and functional analysis of a dendrimer microbicide against HIV-1 env, Cath Latham, Burnet Institute, Australia

6.30 – 6.45 pm Study of the role of gp120 disulfide bridges and N-glycans in HIV capture and transmission, Leen Mathys, Rega Institute for Medical Research, Belgium

6.45 – 7.00 pm Synthesis and biological evaluation of new dual inhibitors of HIV-1 associated functions, Rita Meleddu, University of Cagliari,  Italy.

8:30 pm Sardinian Dinner

Tuesday, October 2nd

Breakfast

Morning session

9.00 – 9.45 am Can novel antiretroviral strategies be deduced from the study of host-retrovirus interplay recorded in vertebrate genomes? Jonas Blomberg,  Uppsala University, Sweden.

9.55 – 10.40 am Feature-based Pharmacophores for Rapid Compound Profiling, Thierry Langer, Prestwick Chemical SAS, Strasbourg-Illkirch, France

10.50 – 11.10 am Coffee break

11:15 – 12.00 pm HIV/AIDS: One virus (HIV-1) and two challenging targets (GP120 and RT dimerization). Strategies for the design and discovery of inhibitors, María José Camarasa, Instituto de Qímica Médica (IQM-CSIC), Madrid, Spain

12.10 – 12:55 pm A Small Molecule Platform to Inhibit HIV through the Nucleocapsid Protein, Daniel H. Appella, National Institutes of Health, Bethesda, MD, USA

1:00 pm Lunch

Afternoon session

3.30 – 5:00 pm Thematic Group Discussions

5:00 – 6.00 pm Coffee break/ Poster Session 2

Short Talks

6.00 – 6.15 pm The mechanism of action of new HIV-1 reverse transcriptase dual inhibitors explored by kinetic studies and site direct mutagenesis, Angela Corona, University of Cagliari, Italy

6.15 – 6.30 pm Optimization of an in vitro assay to quantify HIV-1 Reverse Transcriptase (RT) dimerization, Tania Matamoros, Centro de Biología Molecular “Severo Ochoa”, CSIC-UAM, Madrid, Spain

6.30 – 6.45 pm Formation of HCV replication complex on membranous web: An interplay between viral and cellular factors, Vikas Saxena, Academia Sinica, Taipei, Taiwan

6.45 – 7.00 pm Transmitted and secondary antiretroviral drug resistance among Ethiopian patients, Andargachew Mulu Meharie, University of Leipzig, Leipzig, Germany

8:30 pm Sardinian Dinner

Wednesday, October 3rd

Breakfast

Morning session

9.00 – 9.45 am G-quadruplex nucleic acid conformations: potentially selective targets against viral and cancer diseases, Stefano Alcaro, Università “Magna Græcia” di Catanzaro, Italy

9.55 – 10.40 am High Throughput Screening for Inhibitors of Human Immunodeficiency Virus Ribonuclease H Activity, Stuart F.J. Le Grice, NCI, Frederick, MD, USA

10.50 – 11.10 am Coffee break
11:15 – 12.00 pm Innate Immunity and RNA viruses, Ali Mirazimi, Karolinska Institute, Sweden
12.10 – 12:55 pm to be announced

1:00 pm Lunch

Afternoon session

3.30 – 5:00 pm Thematic Group Discussions

5:00 – 6.00 pm Coffee break/ Poster Session 2

Short Talks

6.00 – 6.15 pm Biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and resistance mutations M41L, L210W and T215Y, Gilberto Betancor, Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, Spain

6.15 – 6.30 pm Characterization of retroviral resistance mechanisms against azidothymidine, Anna Schneider, Department of Biopolymers, University of Bayreuth, Germany

6.30 – 6.45 pm The Ephrin Receptor Tyrosine Kinase A2 is a Cellular Receptor for Kaposi’s Sarcoma-Associated Herpesvirus, Saipraisad Salvi, Institut für Klinische und Molekulare Virologie, Erlangen, Germany

6.45 – 7.00 pm Ebola virus recombinant VP35 (rVP35) as a paradigm model for dsRNA binding-mediated suppression of the interferon-α/β innate immune response, Luca Zinzula, University of Cagliari, Italy

Final remarks

8:30 pm Gala Dinner

Thursday, October 4th- Breakfast and Departure

credits unica.it Università degli Studi di Cagliari
C.F.: 80019600925 - P.I.: 00443370929
note legali | privacy